BCMA is a transmembrane glycoprotein specifically overexpressed on the surface of multiple myeloma (MM) cells.183 After binding to BCMA, belantamab mafodotin is rapidly internalized, degraded in lysosomes to release impermeable MMAF inside MM cells. The gene discussed is CD53; the disease is Miyoshi myopathy.